While everyone is focused on the 100% sensitivity headline, the quieter number might matter just as much: 33% revenue growth year over year in 2024.
Mainz Biomed, ticker MYNZ, reported that its lab network business grew 33% in 2024, per its last annual update. For a small diagnostic company, that is not trivial. It shows there is actual commercial activity behind the story, not just a pre revenue biotech pitch.
Now layer that with what they are doing in 2026.
They raised $6M in fresh capital, appointed a new chairman, and publicly stated they are pivoting toward their U.S. pancreatic cancer program. At the same time, they are exploring potential asset sales of non core colorectal assets and winding down parts of their German subsidiary to cut costs.
That is a full strategic reset.
The pancreatic program is where this gets interesting. Their feasibility study showed 100% sensitivity and about 95% specificity in detecting pancreatic cancer using a blood based mRNA signature. Sensitivity means how well the test detects true positives. Specificity measures how well it avoids false positives. Both numbers matter.
Pancreatic cancer is one of the deadliest cancers because it is usually caught late. A blood based early detection test, if validated in larger trials, could be a major value driver.
This is still high risk. They previously executed a reverse split in 2024 to maintain Nasdaq listing compliance. They rely on capital markets. Additional dilution is possible.
But directionally, MYNZ looks like it is simplifying operations, trimming overhead, and focusing on a single high impact U.S. opportunity.
In small cap biotech, clarity of strategy can matter as much as cash.
NFA